International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.27 Million USD | 1.86% |
| 2022 | 5.09 Million USD | -17.33% |
| 2021 | 6.16 Million USD | -14.0% |
| 2020 | 7.16 Million USD | -36.41% |
| 2019 | 11.26 Million USD | 7.37% |
| 2018 | 10.49 Million USD | 2.12% |
| 2017 | 10.27 Million USD | 2.03% |
| 2016 | 10.07 Million USD | 0.13% |
| 2015 | 10.05 Million USD | -26.98% |
| 2014 | 13.77 Million USD | 14.32% |
| 2013 | 12.05 Million USD | -8.07% |
| 2012 | 13.1 Million USD | -8.14% |
| 2011 | 14.26 Million USD | 26.21% |
| 2010 | 11.3 Million USD | 50.14% |
| 2009 | 7.53 Million USD | 27.49% |
| 2008 | 5.9 Million USD | -2.71% |
| 2007 | 6.07 Million USD | 6.75% |
| 2006 | 5.68 Million USD | 68459.84% |
| 2005 | 8296.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.39 Million USD | -2.1% |
| 2024 Q2 | 1.24 Million USD | -9.29% |
| 2023 Q4 | 1.42 Million USD | 10.86% |
| 2023 Q1 | 1.26 Million USD | 2.19% |
| 2023 Q2 | 1.27 Million USD | 0.95% |
| 2023 FY | 5.18 Million USD | 1.86% |
| 2023 Q3 | 1.28 Million USD | 1.34% |
| 2022 Q2 | 1.27 Million USD | 0.63% |
| 2022 FY | 5.09 Million USD | -17.33% |
| 2022 Q4 | 1.23 Million USD | -6.09% |
| 2022 Q3 | 1.31 Million USD | 2.74% |
| 2022 Q1 | 1.27 Million USD | -11.25% |
| 2021 Q2 | 1.46 Million USD | -8.76% |
| 2021 Q3 | 1.65 Million USD | 12.39% |
| 2021 FY | 6.16 Million USD | -14.0% |
| 2021 Q1 | 1.61 Million USD | 2.81% |
| 2021 Q4 | 1.43 Million USD | -13.33% |
| 2020 Q2 | 1.92 Million USD | -1.69% |
| 2020 FY | 7.16 Million USD | -36.41% |
| 2020 Q3 | 1.71 Million USD | -10.86% |
| 2020 Q4 | 1.56 Million USD | -8.74% |
| 2020 Q1 | 1.95 Million USD | -49.6% |
| 2019 Q1 | 2.86 Million USD | 8.19% |
| 2019 Q4 | 3.88 Million USD | 84.12% |
| 2019 FY | 11.26 Million USD | 7.37% |
| 2019 Q2 | 2.4 Million USD | -16.09% |
| 2019 Q3 | 2.11 Million USD | -12.27% |
| 2018 Q2 | 2.3 Million USD | -22.85% |
| 2018 Q4 | 2.64 Million USD | 4.17% |
| 2018 FY | 10.49 Million USD | 2.12% |
| 2018 Q1 | 2.99 Million USD | -4.74% |
| 2018 Q3 | 2.54 Million USD | 10.13% |
| 2017 Q3 | 2.34 Million USD | 2.18% |
| 2017 FY | 10.27 Million USD | 2.03% |
| 2017 Q1 | 2.49 Million USD | 3.74% |
| 2017 Q4 | 3.14 Million USD | 34.1% |
| 2017 Q2 | 2.29 Million USD | -8.21% |
| 2016 FY | 10.07 Million USD | 0.13% |
| 2016 Q4 | 2.4 Million USD | -7.35% |
| 2016 Q3 | 2.59 Million USD | -2.26% |
| 2016 Q2 | 2.65 Million USD | 10.52% |
| 2016 Q1 | 2.4 Million USD | -2.2% |
| 2015 Q3 | 2.19 Million USD | -1.92% |
| 2015 Q2 | 2.23 Million USD | -29.46% |
| 2015 FY | 10.05 Million USD | -26.98% |
| 2015 Q1 | 3.17 Million USD | -11.94% |
| 2015 Q4 | 2.46 Million USD | 12.18% |
| 2014 FY | 13.77 Million USD | 14.32% |
| 2014 Q4 | 3.6 Million USD | 3.48% |
| 2014 Q1 | 3.27 Million USD | 4.33% |
| 2014 Q2 | 3.42 Million USD | 4.49% |
| 2014 Q3 | 3.47 Million USD | 1.67% |
| 2013 Q4 | 3.13 Million USD | 7.28% |
| 2013 FY | 12.05 Million USD | -8.07% |
| 2013 Q1 | 2.65 Million USD | -24.71% |
| 2013 Q2 | 3.32 Million USD | 25.24% |
| 2013 Q3 | 2.92 Million USD | -11.87% |
| 2012 Q4 | 3.52 Million USD | 19.48% |
| 2012 FY | 13.1 Million USD | -8.14% |
| 2012 Q1 | 3.47 Million USD | -0.85% |
| 2012 Q2 | 3.16 Million USD | -8.76% |
| 2012 Q3 | 2.94 Million USD | -6.98% |
| 2011 Q3 | 3.6 Million USD | -0.22% |
| 2011 Q2 | 3.61 Million USD | 6.21% |
| 2011 FY | 14.26 Million USD | 26.21% |
| 2011 Q1 | 3.39 Million USD | 13.52% |
| 2011 Q4 | 3.5 Million USD | -2.8% |
| 2010 Q2 | 3.07 Million USD | 34.23% |
| 2010 Q1 | 2.29 Million USD | 38.86% |
| 2010 FY | 11.3 Million USD | 50.14% |
| 2010 Q3 | 3.13 Million USD | 1.96% |
| 2010 Q4 | 2.99 Million USD | -4.62% |
| 2009 Q1 | 1.77 Million USD | 28.75% |
| 2009 Q4 | 1.65 Million USD | -23.71% |
| 2009 Q3 | 2.16 Million USD | -2.75% |
| 2009 Q2 | 2.22 Million USD | 25.25% |
| 2009 FY | 7.53 Million USD | 27.49% |
| 2008 Q4 | 1.38 Million USD | 18.88% |
| 2008 Q2 | 1.74 Million USD | 7.28% |
| 2008 Q1 | 1.62 Million USD | 4.0% |
| 2008 FY | 5.9 Million USD | -2.71% |
| 2008 Q3 | 1.16 Million USD | -33.29% |
| 2007 FY | 6.07 Million USD | 6.75% |
| 2007 Q4 | 1.56 Million USD | 8.94% |
| 2007 Q1 | 1.72 Million USD | -69.5% |
| 2007 Q2 | 1.73 Million USD | 0.35% |
| 2007 Q3 | 1.43 Million USD | -17.35% |
| 2006 Q2 | 1122.00 USD | -91.19% |
| 2006 FY | 5.68 Million USD | 68459.84% |
| 2006 Q1 | 12.74 Thousand USD | 0.0% |
| 2006 Q4 | 5.66 Million USD | 54419.36% |
| 2006 Q3 | 10.38 Thousand USD | 825.85% |
| 2005 FY | 8296.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -294.704% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -4.541% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 82.164% |
| Nascent Biotech, Inc. | 2.22 Million USD | -136.381% |
| Rebus Holdings, Inc. | 664 Thousand USD | -693.825% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 85.852% |
| Qrons Inc. | 643.67 Thousand USD | -718.889% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1253.044% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 90.823% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1168.656% |
| Skye Bioscience, Inc. | 13.54 Million USD | 61.093% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 93.926% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -7.18% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1913.938% |
| SQZ Biotechnologies Company | 85.61 Million USD | 93.844% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -80.747% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -250.956% |
| Mesoblast Limited | 5.9 Million USD | 10.691% |
| Marizyme, Inc. | 19.23 Million USD | 72.604% |
| Genus plc | 147.7 Million USD | 96.431% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 39.961% |
| Pharming Group N.V. | 225.49 Million USD | 97.662% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -157.284% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -292.905% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 36.791% |
| ContraFect Corporation | 56.88 Million USD | 90.735% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -19.56% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -256.449% |
| IMV Inc. | 37.7 Million USD | 86.022% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -88.901% |
| MultiCell Technologies, Inc. | 567.42 USD | -928841.525% |
| ONE Bio Corp. | 6.44 Million USD | 18.202% |
| Accustem Sciences Inc. | 3.74 Million USD | -40.694% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 93.867% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -890.86% |
| Q BioMed Inc. | 3.43 Million USD | -53.377% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 78.673% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -100.607% |
| Biomind Labs Inc. | 994.18 Thousand USD | -430.185% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 94.693% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -199.543% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 21.539% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -182.723% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 21184.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 67.077% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -187.233% |
| GB Sciences, Inc. | 1.42 Million USD | -271.064% |
| Alpha Cognition Inc. | 9.7 Million USD | 45.691% |
| HST Global, Inc. | 140.9 Thousand USD | -3640.765% |
| CSL Limited | 3.44 Billion USD | 99.847% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -368.571% |
| Halberd Corporation | 74.84 Thousand USD | -6942.837% |
| Enzolytics Inc. | 2.17 Million USD | -141.844% |
| Agentix Corp. | 1.37 Million USD | -284.252% |
| Resverlogix Corp. | 12.71 Million USD | 58.535% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -44.383% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.656% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -404.885% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -119.174% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -233.744% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -54.803% |
| AVAX Technologies, Inc. | 7.31 Million USD | 27.896% |
| Zenith Capital Corp. | 8.94 Million USD | 41.06% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.361% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -30156.587% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -114.677% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2973.308% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -174.402% |
| Kadimastem Ltd | 2.41 Million USD | -118.704% |
| Helix BioMedix, Inc. | 1.97 Million USD | -167.287% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 51.495% |
| BioStem Technologies, Inc. | 22.97 Million USD | 77.057% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2804.372% |
| LadRx Corporation | 3.81 Million USD | -38.281% |
| Cell Source, Inc. | 4.32 Million USD | -21.863% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -470.757% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -470.757% |
| NovAccess Global Inc. | 2.46 Million USD | -113.681% |
| Affymax, Inc. | 39.38 Million USD | 86.617% |
| Itoco Inc. | 919.14 Thousand USD | -473.469% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -24.363% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -371.046% |
| Mobile Lads Corp. | 554.54 Thousand USD | -850.507% |
| CytoDyn Inc. | 18.05 Million USD | 70.811% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -20842.429% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -2295.06% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -271.252% |
| SYBLEU INC | 160.87 Thousand USD | -3176.437% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -190.202% |
| Bioxytran, Inc. | 3.82 Million USD | -37.979% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -9912.917% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -25810.633% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 85.466% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -225.773% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -616.329% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -69.431% |
| Neutra Corp. | 243.82 Thousand USD | -2061.832% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 69.806% |
| PureTech Health plc | 144.59 Million USD | 96.355% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 74.275% |
| IXICO plc | 4.7 Million USD | -11.982% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 40.082% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 95.523% |
| CSL Limited | 3.89 Billion USD | 99.865% |
| Cellectis S.A. | 97.32 Million USD | 94.584% |